BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6332298)

  • 1. Reduction of phagocyte adherence by nephritic sera: relation to complement activation.
    Strife CF; Ruley EJ
    Pediatr Res; 1984 Jul; 18(7):637-42. PubMed ID: 6332298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.
    Whaley K; Ward D; Ruddy S
    Clin Exp Immunol; 1979 Jan; 35(1):101-6. PubMed ID: 85507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases (author's transl)].
    Berthoux FC; Freyria AM
    Nephrologie; 1980; 1(2):61-6. PubMed ID: 7301022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III.
    Varade WS; Forristal J; West CD
    Am J Kidney Dis; 1990 Sep; 16(3):196-206. PubMed ID: 2205097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Circulating immune complexes, detection in human glomerulonephritis by the PEG-EDTA technique (author's transl)].
    Laurent B; Gonthier R; Genin C; Toulon J; Laurent P; Sabatier JC; Berthoux FC
    Pathol Biol (Paris); 1982 Mar; 30(3):141-6. PubMed ID: 6808442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of (C1INH)2 C1r-C1s complexes in glomerulonephritis as an indicator of C1 activation.
    Waldo FB; West CD
    Clin Immunol Immunopathol; 1987 Feb; 42(2):239-49. PubMed ID: 3026704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Vanes LA
    Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of properdin in normal subjects and patients with renal disease.
    Ziegler JB; Rosen FS; Alper CA; Grupe W; Lepow IH
    J Clin Invest; 1975 Sep; 56(3):761-7. PubMed ID: 1159085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
    Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
    Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
    Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J
    J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating immune complexes and complement levels in hemophilic children.
    Verroust F; Adam C; Kourilsky O; Allain JP; Verroust P
    J Clin Lab Immunol; 1981 Sep; 6(2):127-30. PubMed ID: 6912882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases].
    Takada K; Morishita M; Sugiura T; Suzuki M; Torii Y; Ichimura K; Hashigami H; Toshikawa K; Ina Y; Yamamoto M; Oyama A; Urata A
    Gan No Rinsho; 1983 Apr; 29(4):A-19, 293-6. PubMed ID: 6602233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.
    Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K
    Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.